A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.

BACKGROUND

Moxifloxacin, a fluoroquinolone, has demonstrated its safety and effectiveness in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis.

OBJECTIVE

The aim of this article was to provide a synthesis and critical appraisal of economic evaluations of the management of respiratory tract infections with moxifloxacin.

METHODS

Studies were included if they assessed the costs and consequences of moxifloxacin as compared with an alternative antimicrobial in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis.

RESULTS/

CONCLUSIONS

Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis with moxifloxacin is equally or more effective and less expensive than treatment with other antimicrobials.